Penn State to lead new international Center Of Excellence for malaria research
The 10 new centers will address research needs in regions where malaria is endemic, including parts of Africa, Asia, the Pacific Islands and Latin America. The Southeast Asia center will be a collaborative effort among Penn State, the University of California-Irvine and several institutions in China, Thailand and Myanmar.
"Southeast Asia accounts for 30 percent of global malaria morbidity and 8 percent of global mortality," Cui said. "We will build an international malaria center in this region that brings together diverse expertise from outstanding institutions to address urgent problems relevant to both regional and global malaria control." Cui noted that various factors make malaria control a particular challenge in the region.
"Different forms of the malaria parasite in Southeast Asia are carried by different vectors, each requiring different treatment," he said. "This is magnified by the limited scientific knowledge on the complex interaction between the human host, mosquito vectors and the parasite.
"There also are issues related to emerging drug resistance in Plasmodium falciparum, which causes the most serious form of the disease, as well as problems with fake and counterfeit drugs circulating in the region," he explained. "In addition, political instability and transmigration along border areas pose special challenges in disease surveillance, diagnosis, treatment and control."
The center will undertake scientific research under four project areas:
1. "Malaria epidemiology in Southeast Asia: inter- and intra-country dynamics" will develop and evaluate integrated malaria-control strategies in multiple sites with varying epidemiological conditions.
2. "The malaria vectorial system and new vector-control tools in Southeast Asia" aims to understand the ecology of malaria vectors in the region and to develop innovative malaria-transmission surveillance and control tools.
3. "Antimalarial drug resistance in P. falciparum" is designed to determine the genetic mechanism of drug resistance in malaria parasite populations.
4. "Development of monoclonal antibody-based assays for detection and quantification of artemisinin derivatives" will develop methods for monitoring drug quality control.
"The participating institutions have internationally recognized investigators with a history of collaborations in malaria research and training," Cui said. "By selecting study sites in the most impoverished areas of Myanmar, China and Thailand, this consortium will shed new light on the urgent scientific questions surrounding regional and global malaria control."
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.